UroGen Pharma Ltd. Files 2024 10-K
Ticker: URGN · Form: 10-K · Filed: Mar 10, 2025 · CIK: 1668243
| Field | Detail |
|---|---|
| Company | Urogen Pharma Ltd. (URGN) |
| Form Type | 10-K |
| Filed Date | Mar 10, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, financials, pharmaceuticals
TL;DR
UroGen Pharma 2024 10-K: $32.5M Revenue, $488K Net Income. Assets $100M, Liabs $42.2M.
AI Summary
UroGen Pharma Ltd. filed its 2024 10-K on March 10, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company's total assets were $100,000,000, with total liabilities amounting to $42,231,746. Revenue for the period was $32,490,119, and net income was $487,787. The filing details their business operations and financial standing.
Why It Matters
This 10-K filing provides investors and stakeholders with a comprehensive overview of UroGen Pharma's financial health and operational performance for the fiscal year 2024, including key figures like revenue and net income.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, UroGen Pharma faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the industry.
Key Numbers
- $100.0B — Total Assets (Represents the company's total resources as of December 31, 2024.)
- $42.2B — Total Liabilities (Indicates the company's total obligations as of December 31, 2024.)
- $32.5B — Revenue (The total income generated from sales for the fiscal year 2024.)
- $0.5B — Net Income (The company's profit after all expenses for the fiscal year 2024.)
Key Players & Entities
- UroGen Pharma Ltd. (company) — Filer of the 10-K report
- 2024-12-31 (date) — Fiscal year end date
- 2025-03-10 (date) — Filing date of the 10-K
- $100,000,000 (dollar_amount) — Total assets reported
- $42,231,746 (dollar_amount) — Total liabilities reported
- $32,490,119 (dollar_amount) — Revenue for the fiscal year
- $487,787 (dollar_amount) — Net income for the fiscal year
FAQ
What was UroGen Pharma Ltd.'s total revenue for the fiscal year ending December 31, 2024?
UroGen Pharma Ltd.'s total revenue for the fiscal year ending December 31, 2024, was $32,490,119.
What was the net income reported by UroGen Pharma Ltd. for the fiscal year 2024?
UroGen Pharma Ltd. reported a net income of $487,787 for the fiscal year 2024.
What were UroGen Pharma Ltd.'s total assets as of December 31, 2024?
As of December 31, 2024, UroGen Pharma Ltd.'s total assets were $100,000,000.
What were UroGen Pharma Ltd.'s total liabilities as of December 31, 2024?
UroGen Pharma Ltd.'s total liabilities as of December 31, 2024, amounted to $42,231,746.
When did UroGen Pharma Ltd. file its 10-K report for the fiscal year 2024?
UroGen Pharma Ltd. filed its 10-K report for the fiscal year 2024 on March 10, 2025.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 10, 2025 regarding UroGen Pharma Ltd. (URGN).